-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Maintains Overweight on Protagonist Therapeutics, Raises Price Target to $180

Benzinga·09/01/2026 18:44:21
Listen to the news
Barclays analyst Etzer Darout maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Overweight and raises the price target from $153 to $180.